157
A
Abnormally shaped waveforms, 9
Abnormally wide or narrow pulse
pressure, 9–10
ABO incompatibility, 24
Absence of breathing. See Apnea
Acidosis, 25
Air leaks
mechanical ventilation and, 80
surfactant therapy and, 105
Albuterol, 140
Aldactone, 141
Alkalosis, 25
Alveoli
collapsed, 98
normal, 98
Aminophylline, 140
Anemia
monitoring for, 123–125
severe, 33, 35
Anticonvulsant drugs, 146
Apnea
mechanical ventilation and, 74, 77
monitoring for, 121–123
Arterial blood gases
chronic lung disease and, 144
mechanical ventilation and, 78, 80
surfactant therapy and, 102
Arterial catheter, 4
Aspiration syndrome, 99
surfactant therapy for, 104
Assessment
of family, 128–129, 147
of growth, 118–121, 146
Assisted ventilation. See Mechanical
ventilation
B
Blocked or displaced endotracheal
tubes and mechanical
ventilation, 80
Blood
amount used for exchange trans-
fusion, 25
preparation for exchange transfu-
sion, 25
preservation, 24–25
types of donors, 24
urea nitrogen, 145
Blood pressure, 2
calibration of the monitor, 16–17
equipment needed, 4–5
measuring, 17
method of measurement, 4
monitoring types, 4
normal ranges, 6–7
posttest, 12
pretest, 3
self-tests, 5, 10–11
transducer monitoring, 5, 10–11,
13–17
waveforms interpretation, 8–10
Body weight, 120
Bradycardia, 123
BUN. See Blood, urea nitrogen
C
Caffeine, 141
Calibration, blood pressure monitor,
16–17
Cardiac complications of exchange
transfusions, 29
Catheter, arterial, 4, 9
Catheter, peripheral arterial (PAC),
23, 32
Catheter, umbilical arterial (UAC),
23, 27, 32
Catheter, umbilical venous (UVC),
23, 26–28, 32
CHD. See Congenital heart disease
(CHD)
Chest movement and mechanical
ventilation, 79
Chest radiographs, 142, 148
Chlorothiazide, 141
Cholestatic jaundice, 137
Chronic lung disease (CLD), 136,
140–144
Citrate phosphate dextrose adenine
(CPDA-1), 24, 25
CLD. See Chronic lung disease
(CLD)
Clots
within catheters, 9
complications of exchange trans-
fusions, 29
exchange transfusion and, 27
Commercial stabilizers, 86–90
Complications, potential
direct transfusion, 36
exchange transfusions, 28–29,
32–33
mechanical ventilation, 80–81
surfactant therapy, 104–105
Congenital heart disease (CHD),
138, 147–148
Continuing care, 112, 115
administering immunizations
during, 125
assessment of family during,
128–129, 147
assessment of growth during,
118–121
assessment of head growth dur-
ing, 147
cholestatic jaundice and, 137
chronic lung disease and, 136,
140–144
congenital heart disease and, 138,
147–148
developmental care and, 129
discharge and, 132–134
gastroesophageal reflux and, 136
hearing deficits and, 126
hydrocephalus and, 137, 146
late head ultrasound during, 128
monitoring and treatment
guidelines for babies with
special problems,
140–148
monitoring for anemia during,
123–125
monitoring for apnea during,
121–123
patent ductus arteriosus and, 138
posttest, 153
pretest, 113–114
recommended routines, 149
retinopathy of prematurity and,
126–127, 144–145
seizures and, 137, 146
self-tests, 130–131, 135, 139,
150–152
short bowel syndrome and, 137,
145–146
sleep position/environment and,
128
special problems that may be
encountered in babies
requiring, 136–138,
140–148
specific issues involved in,
115–131
temperature control during,
115–116
which babies require, 115
Continuous method of exchange
transfusion, 26–27, 32,
49, 50
Index
Previous Page Next Page